Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 19/20 | 0.45 |
| ▸ | ESR1 | P03372 | 18/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2421076 | 0.90 | ESR2 (0.44) | ESR2ESR1 | |
| SCHEMBL2418558 | 0.90 | ESR2 (0.46) | ESR2ESR1 | |
| SCHEMBL2418941 | 0.90 | ESR2 (0.48) | ESR2ESR1 | |
| SCHEMBL2420181 | 0.87 | ESR2 (0.41) | ESR2ESR1THRATHRB | |
| SCHEMBL2418449 | 0.87 | ESR2 (0.41) | ESR2ESR1THRATHRB | |
| SCHEMBL2412936 | 0.85 | ESR2 (0.42) | ESR2ESR1THRATHRB | |
| SCHEMBL2422236 | 0.83 | ESR2 (0.67) | ESR2ESR1 | |
| SCHEMBL2418604 | 0.82 | ESR2 (0.45) | ESR2ESR1 | |
| SCHEMBL4861051 | 0.81 | ESR2 (0.59) | ESR2ESR1 | |
| SCHEMBL2413798 | 0.81 | ESR2 (0.67) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257264-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | disclosed |
| US-7087599-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1257264-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050137192-A1 | Estrogen receptor modulators | PARKER DANN R JR (US) | 2005-06-23 | — | — | US | disclosed |
| US-20030027840-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2003-02-06 | — | — | US | disclosed |
| EP-1257264-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001082923-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027840-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | ESR2 2/4885ESR1 5/4885THRA 249/4885 |
| US-20050137192-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | ESR2 2/4885ESR1 5/4885THRA 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.